Objective: Germ line mutations of the LKB1 gene cause the autosomal dominant Peutz-Jeghers syndrome (PJS), and PJS has also been associated with an increased risk of developing cancers, suggesting LKB1 may act as a tumor suppressor in PJS. By contrast, LKB1 mutations are rare events in most sporadic tumors in non-PJS patients, except for lung cancers. To better understand the involvement of LKB1 gene alterations during lung carcinogenesis, we investigated the LKB1 gene mutations and expressions in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine (BHP) in rats. Methods: Male Wistar rats, 6 weeks old, were given 2,000 ppm BHP in their drinking water for 12 weeks and maintained without further treatment until they were sacrificed at 25 weeks. A total of 15 lung adenocarcinomas were obtained, and genomic DNA was extracted for the search of mutations using polymerase chain reaction (PCR)-single strand conformation polymorphism analysis. To assess altered expressions of the LKB1 gene, reverse transcription-PCR analysis was also performed. Results: No mutations were found throughout exons 1–9 in any of the tumors. Aberrant transcripts bearing deletions of nucleotides 216–1459, 289–1302, 268–1261, or 257–1378 were detected in 5 of 15 adenocarcinomas (33.3%). Conclusion: These results suggest that alterations of the LKB1 gene might be involved in the development of lung adenocarcinomas induced by BHP in rats.

Keywords:
LKB1, Lung adenocarcinoma, Nitrosamine
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.